Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 10/20 | 0.53 |
| ▸ | F11 | P03951 | 4/20 | 0.53 |
| ▸ | F7 | P08709 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231164 | 0.81 | F9 (0.47) | F9F11F7CYP2C9F10 | |
| SCHEMBL787083 | 0.77 | ADORA3 (0.47) | F9F11F7CYP2C9IRAK4 | |
| SCHEMBL9607737 | 0.73 | IRAK4 (0.42) | IRAK4ADORA3ADORA2AADORA1 | |
| SCHEMBL9607742 | 0.71 | DRD3 (0.43) | F9F11F7CYP2C9F10 | |
| SCHEMBL1233112 | 0.69 | F9 (1.00) | F9F11F7CYP2C9F10 | |
| SCHEMBL9607739 | 0.68 | TP53 (0.45) | IRAK4ADORA3ADORA2AADORA1 | |
| SCHEMBL6918463 | 0.68 | F9 (0.76) | F9F11F7CYP2C9F10 | |
| SCHEMBL9607736 | 0.67 | ADORA1 (0.51) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1232830 | 0.67 | F9 (0.72) | F9F11F7CYP2C9F10 | |
| SCHEMBL6918539 | 0.66 | F9 (0.71) | F9F11F7CYP2C9F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | F9 1/4885F11 5/4885F7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.